author-photo

Thomas J. Herzog

University of Cincinnati

129

Papers

2316

Citations

Citation Trend

Filter By

Papers (91) Sort By

Journal Conference Others

Phase 1b study of GAS6/AXL inhibitor (AVB-500) in recurrent, platinum-resistant ovarian carcinoma.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A comprehensive landscape of BRCA1 versus BRCA2 associated molecular alterations and survival outcome across 35 cancer types.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
The GOG partners: A program for industry sponsored clinical trials in gynecologic oncology within the GOG foundation.

2021 Gynecologic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Phase I study of GAS6/AXL inhibitor (AVB-500) in recurrent, platinum-resistant ovarian carcinoma

2021 Gynecologic Oncology
Show All
- Source
- Cite
- Save
Citations (1)
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.

2021 International Journal of Gynecological Cancer
Show All
- Source
- Cite
- Save
Citations (1)
Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer.

2021 Gynecologic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy/safety of farletuzumab in combination with carboplatin plus paclitaxel or carboplatin plus pegylated liposomal doxorubicin (PLD) in women with low CA-125 platinum-sensitive ovarian cancer

2021 Gynecologic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.

2021 Gynecologic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Assessment of immune biomarkers and establishing a triple negative phenotype in gynecologic cancers.

2021 Gynecologic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer.

2021 Cancer Gene Therapy
Show All
- Source
- Cite
- Save
Citations (1)